Dexcom Executive Chair Kevin R. Sayer sold 26,756 shares on July 20, 2026 at an average price of $76.32, for proceeds of about $2.04 million. The company noted the transaction was made under a pre-scheduled Rule 10b5-1 trading plan, which is set up in advance and can help reduce concerns that a sale was driven by nonpublic information. Sayer’s role as Executive Chair makes his transactions worth watching because he is a senior leader with deep visibility into strategy and governance, even if he is not running day-to-day operations. That said, sales by insiders can happen for many personal reasons, and a 10b5-1 plan typically indicates the trade was planned ahead of time rather than a reaction to recent developments. Looking at the past 30 days, insider activity at Dexcom has been limited and skewed toward selling: Sayer’s $2.04 million sale and a smaller sale by Michael Jon Brown ($126.5K) on July 15. With only two reported transactions and both being sales, the main takeaway is that insiders have been taking some money off the table recently, but the presence of a 10b5-1 plan makes this particular sale less informative about management’s view of near-term business conditions.